On the heels of solid tumor data and with competitors surging, Poseida scraps autologous CAR-T in favor of allo

Amber Tong

Poseida CEO Eric Ostertag was not shy about the prospects he sees for autologous CAR-T therapies in the age of off-the-shelf alternatives: They are going …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

On the heels of solid tumor data and with competitors surging, Poseida scraps autologous CAR-T in favor of allo

Amber Tong

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

AstraZeneca’s SERD hits primary endpoint in late-stage trial, but first-line potential remains uncertain

Updated: Lilly joins Trump administration to announce $27B manufacturing commitment

Eikon Therapeutics raises $351M Series D as lead drug starts Phase 3

CBER's deputy director departs as staff shakeup continues

Regeneron, two Chinese biotechs tout promise of their hearing loss gene therapies

How AI can address ongoing challenges in the life sciences industry

On the heels of sol­id tu­mor da­ta and with com­peti­tors surg­ing, Po­sei­da scraps au­tol­o­gous CAR-T in fa­vor of al­lo

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

On the heels of solid tumor data and with competitors surging, Poseida scraps autologous CAR-T in favor of allo